Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel diseases (IBD), including ulcerative colitis (UC), involve chronic gastrointestinal inflammation.
• Corticosteroid resistance or dependence affects approximately 20% of severe UC cases.
• Tacrolimus, a calcineurin inhibitor, is emerging as a treatment option for steroid-refractory UC.

Purpose of the Study:

• To review the mechanism of action of tacrolimus in ulcerative colitis.
• To evaluate the efficacy and safety of tacrolimus for steroid-refractory UC.
• To discuss the pharmacogenetics influencing tacrolimus treatment response.

Main Methods:

• Literature review of studies on tacrolimus in ulcerative colitis.
• Analysis of clinical trial data regarding efficacy and adverse events.
• Examination of pharmacogenetic studies related to tacrolimus.

Main Results:

• Tacrolimus demonstrates notable therapeutic efficacy in inducing and maintaining remission in UC patients.
• Treatment with tacrolimus does not appear to increase the risk of severe adverse effects.
• Pharmacogenetic factors may influence individual patient responses to tacrolimus.

Conclusions:

• Tacrolimus is a promising therapeutic option for patients with severe, steroid-refractory ulcerative colitis.
• Its efficacy in both remission induction and maintenance supports its use in challenging UC cases.
• Further research into pharmacogenetics can optimize tacrolimus therapy for UC patients.